When it was approved in 2003 as the first new laser in five years, the FDA granted ALLEGRETTO WAVE the widest approval range ever initially given to a new laser for both myopic and hyperopic vision correction. Since then, the results have been astoundingly positive. Allegretto Wave has been proven to provide excellent clinical results, as shown by the following statistics that were reported to the FDA:
- At one year after treatment, more than 93% of patients said they saw at least as well or better than they had with glasses or contacts before treatment.
- More than 98% of patients achieved 20/40 vision one year after treatment; 20/40 is the level of visual acuity required to pass most driving tests.
- Nearly 60% of near-sighted patients achieved 20/16 vision after one year of treatment.
- Both near-and far-sighted patients reported an improvement in their reaction to bright lights and night driving glare after Allegretto Wave treatments. In addition, near-sighted patients reported an improvement in sensitivity to light.
- Predictable results are the norm for the Allegretto Wave. More than 90% of patients achieve refraction within 1 diopter of their target correction.
- The Allegretto Wave has a total re-treatment rate of less than 5% of patients.
A great source for information about LASIK and questions to ask your physician is the FDA website and the website of the American Society of Cataract and Refractive Surgery.
During the consultation with your doctor, please be sure to mention all medications you are taking and any medical conditions you have that might affect the success of laser correction.
For information regarding the risks and benefits associated with the ALLEGRETTO WAVE treatment, please visit www.fda.gov.